Cargando…
PD-L1 expression levels on tumor cells affect their immunosuppressive activity
Programmed cell death 1 (PD-1) is an immuno-checkpoint receptor which is primarily expressed on T cells, monocytes, natural killer cells and macrophages. Programmed death-ligand 1 (PD-L1) is the primary ligand of PD-1 and is constitutively expressed on antigen presenting cells, mesenchymal stem cell...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781757/ https://www.ncbi.nlm.nih.gov/pubmed/31612048 http://dx.doi.org/10.3892/ol.2019.10903 |
_version_ | 1783457434576093184 |
---|---|
author | Zheng, Yang Fang, You-Chen Li, Jing |
author_facet | Zheng, Yang Fang, You-Chen Li, Jing |
author_sort | Zheng, Yang |
collection | PubMed |
description | Programmed cell death 1 (PD-1) is an immuno-checkpoint receptor which is primarily expressed on T cells, monocytes, natural killer cells and macrophages. Programmed death-ligand 1 (PD-L1) is the primary ligand of PD-1 and is constitutively expressed on antigen presenting cells, mesenchymal stem cells and bone marrow-derived mast cells. In addition, PD-L1 is also expressed on a wide range of tumor cells, including lung cancer, breast cancer and melanoma. PD-1 and PD-L1 are important members of the immunoglobulin super-family and participate in immune regulation. In the present study, the immune-suppressive effects of a number of tumor cell lines were determined. The breast tumor cell lines MCF-7 and MDA-MB-231 displayed the largest inhibitory effects on T-cell activation and cytokine secretion in a co-culture system. The HepG2, A549 and A375 cells displayed limited inhibitory effects. MCF-7 and MDA-MB-231 cells expressed the highest level of PD-L1 among the cells used, which may explain their higher immuno-suppressive effects. Compound A0-L, a small molecule inhibitor of the PD-1/PD-L1 interaction, restored T cell functions. Additionally, it was demonstrated that the tumor cells with higher levels of PD-L1 expression suppressed signaling pathways involved in T-cell activation, such as the T-cell receptor- zeta chain of T cell receptor associated protein kinase ZAP70-RAS-GTPase-extracellular-signal-regulated kinases and CD28-PI3K-Akt serine/threonine kinases pathways. These findings suggest that tumor cells with higher expression levels of PD-L1 may exhibit higher immuno-suppressive activity, and that drugs targeting the PD-1/PD-L1 interaction may have improved therapeutic effects on tumors expressing higher levels of PD-L1. |
format | Online Article Text |
id | pubmed-6781757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-67817572019-10-14 PD-L1 expression levels on tumor cells affect their immunosuppressive activity Zheng, Yang Fang, You-Chen Li, Jing Oncol Lett Articles Programmed cell death 1 (PD-1) is an immuno-checkpoint receptor which is primarily expressed on T cells, monocytes, natural killer cells and macrophages. Programmed death-ligand 1 (PD-L1) is the primary ligand of PD-1 and is constitutively expressed on antigen presenting cells, mesenchymal stem cells and bone marrow-derived mast cells. In addition, PD-L1 is also expressed on a wide range of tumor cells, including lung cancer, breast cancer and melanoma. PD-1 and PD-L1 are important members of the immunoglobulin super-family and participate in immune regulation. In the present study, the immune-suppressive effects of a number of tumor cell lines were determined. The breast tumor cell lines MCF-7 and MDA-MB-231 displayed the largest inhibitory effects on T-cell activation and cytokine secretion in a co-culture system. The HepG2, A549 and A375 cells displayed limited inhibitory effects. MCF-7 and MDA-MB-231 cells expressed the highest level of PD-L1 among the cells used, which may explain their higher immuno-suppressive effects. Compound A0-L, a small molecule inhibitor of the PD-1/PD-L1 interaction, restored T cell functions. Additionally, it was demonstrated that the tumor cells with higher levels of PD-L1 expression suppressed signaling pathways involved in T-cell activation, such as the T-cell receptor- zeta chain of T cell receptor associated protein kinase ZAP70-RAS-GTPase-extracellular-signal-regulated kinases and CD28-PI3K-Akt serine/threonine kinases pathways. These findings suggest that tumor cells with higher expression levels of PD-L1 may exhibit higher immuno-suppressive activity, and that drugs targeting the PD-1/PD-L1 interaction may have improved therapeutic effects on tumors expressing higher levels of PD-L1. D.A. Spandidos 2019-11 2019-09-20 /pmc/articles/PMC6781757/ /pubmed/31612048 http://dx.doi.org/10.3892/ol.2019.10903 Text en Copyright: © Zheng et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Zheng, Yang Fang, You-Chen Li, Jing PD-L1 expression levels on tumor cells affect their immunosuppressive activity |
title | PD-L1 expression levels on tumor cells affect their immunosuppressive activity |
title_full | PD-L1 expression levels on tumor cells affect their immunosuppressive activity |
title_fullStr | PD-L1 expression levels on tumor cells affect their immunosuppressive activity |
title_full_unstemmed | PD-L1 expression levels on tumor cells affect their immunosuppressive activity |
title_short | PD-L1 expression levels on tumor cells affect their immunosuppressive activity |
title_sort | pd-l1 expression levels on tumor cells affect their immunosuppressive activity |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781757/ https://www.ncbi.nlm.nih.gov/pubmed/31612048 http://dx.doi.org/10.3892/ol.2019.10903 |
work_keys_str_mv | AT zhengyang pdl1expressionlevelsontumorcellsaffecttheirimmunosuppressiveactivity AT fangyouchen pdl1expressionlevelsontumorcellsaffecttheirimmunosuppressiveactivity AT lijing pdl1expressionlevelsontumorcellsaffecttheirimmunosuppressiveactivity |